Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019
Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31,
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12th, 2020
RANCHO CUCAMONGA, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2019 ended December 31, 2019 , after the market closes on Thursday, March 12th, 2019 , and will hold a conference
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL
RANCHO CUCAMONGA, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%,
View HTML
Toggle Summary Amphastar Announces the Receipt of a MINOR CRL for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
RANCHO CUCAMONGA, Calif. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced that on January 24, 2020 , the U.S. Food and Drug Administration (“FDA”) issued a “ MINOR ” Complete Response Letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference
RANCHO CUCAMONGA, Calif. , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President and Bill Peters , CFO will be presenting at the 31 st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 1:00 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, Calif. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President will be presenting at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 3:20 p.m. GMT in Aldwych, London, UK .
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2019
Reports Net Revenues of $80.1 Million for the Three Months Ended September 30, 2019 RANCHO CUCAMONGA, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2019 .
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7th, 2019
RANCHO CUCAMONGA, Calif. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2019 ended September 30th, 2019 , after the market closes on Thursday, November 7th, 2019 , and will hold a conference
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Wells Fargo 2019 Healthcare Conference
RANCHO CUCAMONGA, Calif. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO, will be presenting at the Wells Fargo 2019 Healthcare Conference on Thursday, September 5, 2019 at 3:05 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2019
Reports Net Revenues of $79.0 Million for the Three Months Ended June 30, 2019 RANCHO CUCAMONGA, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2019 .
View HTML

 

Copyright ©2020 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States